NASDAQ:SGYP Synergy Pharmaceuticals (SGYP) Stock Price, News & Analysis → Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad) Free SGYP Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.01▼$0.0352-Week Range N/AVolumeN/AAverage Volume6.08 million shsMarket Capitalization$7.44 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Synergy Pharmaceuticals alerts: Email Address Ad Banyan Hill PublishingDon’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Synergy Pharmaceuticals Stock (NASDAQ:SGYP)Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. The company also develops dolcanatide to treat mild-to-moderate ulcerative colitis. It has a licensing agreement with Cipher Pharmaceuticals Inc. to develop, market, distribute, and sell TRULANCE in Canada. Synergy Pharmaceuticals Inc. is headquartered in New York, New York. On December 12, 2018, Synergy Pharmaceuticals Inc. along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.Read More Ad Banyan Hill PublishingDon’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him SGYP Stock News HeadlinesApril 12, 2024 | seekingalpha.comJose SolorioJanuary 2, 2024 | msn.comPYC Therapeutics and Google Cloud partner for new precision medicinesApril 24, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.May 9, 2023 | investing.comSynergy Pharmaceuticals Inc Unit (SGYPU)April 12, 2023 | forbes.comMarket Factor Synergy Signals Exciting Growth For Digital PathologyMarch 29, 2023 | bbc.co.ukDifferent resistorsMarch 28, 2023 | bbc.co.ukMains cablesMarch 28, 2023 | bbc.co.ukEnergy changes in brakingApril 24, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.December 18, 2022 | thestreet.comSynergy Pharmaceuticals (SGYP) Stock Higher in After-Hours Trading Following Paulson InvestmentSeptember 13, 2022 | investing.comJiangxi Synergy Pharmaceutical Co Ltd (300636)May 16, 2022 | seekingalpha.comSyros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q1 2022 Results - Earnings Call TranscriptJanuary 18, 2022 | thestreet.comHere's a Reason Why Synergy Pharma (SGYP) Stock Is Rallying TodayDecember 2, 2021 | finanznachrichten.deOKYO Pharma LTD: OKYO Pharma Limited: Directorate ChangeSee More Headlines Receive SGYP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Synergy Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2018Today4/24/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:SGYP CUSIP87163930 CIK1347613 Webwww.synergypharma.com Phone212-297-0020FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-224,330,000.00 Net Margins-332.11% Pretax MarginN/A Return on EquityN/A Return on Assets-118.14% Debt Debt-to-Equity RatioN/A Current Ratio0.52 Quick Ratio0.38 Sales & Book Value Annual Sales$16.82 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / BookN/AMiscellaneous Outstanding Shares248,040,000Free FloatN/AMarket Cap$7.44 million OptionableOptionable Beta4.94 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Troy Hamilton Pharm.D. (Age 47)CEO & Director Mr. Gary G. Gemignani (Age 54)Exec. VP & CFO Gem Gokmen HopkinsVP of Investor Relations and Corp. CommunicationsMs. Pamela CebulskiSr. VP of MarketingMs. Marianne JacksonSr. VP of Sales & Market AccessKey CompetitorsMolecular TemplatesNASDAQ:MTEMChemomab TherapeuticsNASDAQ:CMMBPasithea TherapeuticsNASDAQ:KTTABionomicsNASDAQ:BNOXKinetaNASDAQ:KAView All Competitors SGYP Stock Analysis - Frequently Asked Questions How were Synergy Pharmaceuticals' earnings last quarter? Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced its earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.13) by $0.01. The biopharmaceutical company had revenue of $11.11 million for the quarter, compared to analyst estimates of $15.65 million. What other stocks do shareholders of Synergy Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Synergy Pharmaceuticals investors own include Novavax (NVAX), Immunomedics (IMMU), Progenics Pharmaceuticals (PGNX), Inovio Pharmaceuticals (INO), ACADIA Pharmaceuticals (ACAD), Cara Therapeutics (CARA), OPKO Health (OPK), Gilead Sciences (GILD), Exelixis (EXEL) and This page (NASDAQ:SGYP) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryBiden out June 13; Kamala won’t replace him?Paradigm PressNew Trump BombshellThe Freeport SocietyThe Greatest Bull Market in Crypto History…Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synergy Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.